Subject(s)
Lung Neoplasms , Sarcoma , Humans , Lung Neoplasms/diagnosis , Lung Neoplasms/pathology , Sarcoma/diagnosis , Sarcoma/pathology , Male , Middle Aged , FemaleABSTRACT
Background Readmission occurs in 1 out of 3 patients with heart failure (HF). We aimed to study the incidence and prognostic implications of rehospitalizations because of arterial thromboembolism events (ATEs) and venous thromboembolism events (VTEs) after discharge in patients with HF. Methods and Results We identified Medicare beneficiaries who were admitted with a primary diagnosis of HF from 2014 to 2019, with a hospital stay ranging between 3 and10 days, followed by discharge to home. We calculated incidence of ATEs (myocardial infarction, ischemic stroke, or systemic embolism) and VTEs (deep venous thrombosis and pulmonary embolism) up to 90 days after discharge. Out of 2 953 299 patients admitted with HF during the study period, a total of 585 353 patients met the inclusion criteria, and 36.6% were readmitted within 90 days of discharge. The incidence of readmission due ATEs, VTEs, HF, and all other reasons was 3.4%, 0.5%, 13.2%, and 19.5%, respectively. Incidence of thromboembolic events was highest within 14 days after discharge. Factors associated with ATEs included prior coronary, peripheral, or cerebrovascular disease and for VTEs included malignancy and prior liver or lung disease. ATE/VTE readmission had a 30-day mortality of 19.9%. After a median follow-up period of 25.6 months, ATE and VTE readmissions were associated with higher risk of mortality (hazard ratio, 2.76 [95% CI, 2.71-2.81] and 2.17 [95% CI, 2.08-2.27], respectively; P<0.001 for both) compared with no readmission on time-dependent Cox regression. Conclusions After a HF hospitalization, 3.9% of patients were readmitted with a thromboembolic event that was associated with 2- to 3-fold greater risk of mortality in follow-up.
Subject(s)
Heart Failure , Thrombosis , Venous Thromboembolism , Aged , Heart Failure/complications , Heart Failure/epidemiology , Heart Failure/therapy , Hospitalization , Humans , Incidence , Medicare , Patient Readmission , Prognosis , Retrospective Studies , Risk Factors , Thrombosis/complications , United States/epidemiology , Venous Thromboembolism/diagnosis , Venous Thromboembolism/epidemiology , Venous Thromboembolism/etiologySubject(s)
COVID-19/epidemiology , SARS-CoV-2 , Thrombosis/epidemiology , Adolescent , Adult , Aged , COVID-19/complications , Female , Humans , Incidence , Male , Middle Aged , Thrombosis/etiology , United States/epidemiology , Young AdultABSTRACT
The stenosis or occlusion of extremities defining peripheral artery disease (PAD) is a risk factor for adverse cardiovascular events and adverse limb events including amputation. PAD is common, can occur without symptoms or with claudication, and is easily diagnosed. Proper diagnosis and adherence to guideline-directed therapy can reduce the morbidity and potential mortality associated with PAD.
Subject(s)
Exercise Therapy , Factor Xa Inhibitors/therapeutic use , Intermittent Claudication/drug therapy , Peripheral Arterial Disease/therapy , Platelet Aggregation Inhibitors/therapeutic use , Thrombosis/prevention & control , Vascular Surgical Procedures , Vasodilator Agents/therapeutic use , Ankle Brachial Index , Anticholesteremic Agents/therapeutic use , Cilostazol/therapeutic use , Diet, Healthy , Dual Anti-Platelet Therapy , Endovascular Procedures , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Intermittent Claudication/etiology , Peripheral Arterial Disease/complications , Peripheral Arterial Disease/diagnosis , Peripheral Arterial Disease/physiopathology , Rivaroxaban/therapeutic use , Smoking Cessation , Thrombosis/etiologyABSTRACT
A 49-year-old man with progressive dyspnea on exertion and a remote history of syncope presented with hypotension and acute right ventricular failure, and was ultimately diagnosed with acute pulmonary embolism. Laboratory data revealed a prolonged activated partial thromboplastin time, which confounded treatment options. He was ultimately diagnosed with anti-phospholipid syndrome and factor XII deficiency, and underwent a thromboendarterectomy procedure with resolution of right ventricular failure and symptoms. Careful attention to history, initial physical examination manifestations, and clinical data often permit a timely diagnosis of and treatment for chronic thromboembolic pulmonary hypertension.
